Core Viewpoint - The approval of the inhaled powder formulation of Nintedanib by the National Medical Products Administration of China marks a significant milestone for the company, allowing it to conduct clinical trials for idiopathic pulmonary fibrosis and potentially for other related conditions [1] Company Summary - The stock price of the company increased by 4.13%, reaching HKD 8.83, with a trading volume of HKD 1.153 billion [1] - The approved clinical indication for the product is idiopathic pulmonary fibrosis, with potential applications for systemic sclerosis-related interstitial lung disease and progressive pulmonary fibrosis [1] - The product represents a key achievement of the company's inhalation technology platform, establishing a solid foundation for the development of subsequent inhalation formulations in its pipeline [1]
港股异动 | 石药集团(01093)涨超4% 乙磺酸尼达尼布吸入粉雾剂获批临床